Impact of Adjuvant Abemaciclib on Service Provision within a District General Hospital Cancer Centre

Purpose: Two years of adjuvant abemaciclib with endocrine therapy was approved by NICE [1] in July 2022 for hormone receptor-positive (HR+) HER2-negative (HER2 –) node-positive early breast cancer (EBC) at high-risk of recurrence. There is concern around additional oncology service provision needs of this cohort who would previously have been discharged to surveillance. We have therefore reviewed our service to estimate the impact of this additional trea tment on projected service provision needs.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research